Mabwell (Shanghai) Bioscience Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2017-05-12
- Employees
- 1.4K
- Market Cap
- -
- Website
- https://www.mabwell.com
Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05324592
- Locations
- 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 433
- Registration Number
- NCT05297292
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Si Chuan, China
A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 208
- Registration Number
- NCT05216965
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy and Safety of MW031 in PMO Subjects
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 448
- Registration Number
- NCT05215977
- Locations
- 🇨🇳
Peking Union Hospital, Beijing, Beijing, China
A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection
Phase 1
Completed
- Conditions
- COPDAsthmaAtopic Dermatitis
- Interventions
- Drug: 9MW1911 Injection PlaceboDrug: 9MW1911 Injection
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05170243
- Locations
- 🇨🇳
Shanghai Public Health Center, Shanghai, Shanghai, China
A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
Phase 1
Recruiting
- Conditions
- Advanced Malignant Neoplasm
- Interventions
- Drug: Intravenous Infusion
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 272
- Registration Number
- NCT05048160
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 708
- Registration Number
- NCT04812509
- Locations
- 🇨🇳
Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04798313
- Locations
- 🇨🇳
PKUCare Luzhong Hospital, Zibo, Shandong, China
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04798326
- Locations
- 🇨🇳
PKUCare Luzhong Hospital, Zibo, Shandong, China
A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection
Phase 1
Completed
- Conditions
- Staphylococcus Aureus Infection
- Interventions
- Combination Product: 9MW1411 injection placeboCombination Product: 9MW1411 injection
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04784312
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China